Learn how MDS/CMML-associated lupus differs from classic lupus and why clone-directed therapies may offer better outcomes.

During a live event, Praneeth Baratam, MBBS, discussed the molecular factors that affect staging of lower-risk myelodysplastic syndromes.

Researchers suggest that this dataset could significantly accelerate innovation in AI-based diagnostics for blood disorders.

A study suggests that lupus-like manifestations in patients with MDS/CMML frequently reflect clonal myeloid infiltration.

Researchers discovered that chronic inflammation fundamentally remodels the bone marrow, allowing mutated stem cell clones to ...

ECOG performance status, IPSS risk scores, bone marrow blast percentage, TP53 mutations, and cytogenetic abnormalities independently predicted prognosis. Complete remission significantly improved ...

ABSTRACT: Background and Aim: Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders characterised by ineffective haematopoiesis and an increased risk of progression to acute ...

ABSTRACT: Background and Aim: Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders characterised by ineffective haematopoiesis and an increased risk of progression to acute ...

Nearly two years after federal audits of schizophrenia diagnoses began, most skilled nursing targets are still being accused of labeling patients with a major mental illness without proper ...

HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial ...

MPNs involve overproduction of blood cells, while MDS results in poorly formed cells, affecting blood cell function and counts. Diagnosis requires blood tests, bone marrow biopsy, and genetic testing ...